23 July 2020 - People with cystic fibrosis living in Wales should get speedy access to Vertex' new therapy following its approval by Europe regulators.

The company has agreed a letter of intent with NHS Wales to expand its reimbursement agreement for medicines for cystic fibrosis to include Kaftrio (ivacaftor/tezacaftor/elexacaftor), in a combination regimen with ivacaftor 150 mg, upon the medicine’s anticipated marketing clearance by the European Commission.

Once finalised, the expanded agreement will include reimbursed access for eligible patients to Kaftrio in a combination regimen with ivacaftor, as well as Vertex’ currently licensed medicines Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor) and Symkevi (ivacaftor/tezacaftor).

Read Pharma Times article